Compare Repligen Corporation Common Stock (RGEN) vs Standard Lithium Ltd (SLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Standard Lithium Ltd — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.31B), while Standard Lithium Ltd trades at $1.38 (market cap $345.40M). The key difference: Repligen Corporation Common Stock is far larger — about 32.7× Standard Lithium Ltd's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Standard Lithium Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Standard Lithium Ltd for 24 Days on average.
| RGEN | SLI | |
|---|---|---|
Market Cap | $11.31B | $345.40M |
Volume | 1,216,919 | 2,580,587 |
Sector | Health | Basic Materials |
52-Week High | $194.57 | $5.65 |
52-Week Low | $102.87 | $1.38 |
Typical Hold Time | 0 Days | 24 Days |
Enterprise Value | $11.20B | $208.31M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Standard Lithium (SLI) trades at $1.43, down 4.03% today, with a bearish technical signal despite bullish oscillators. The company shows negative profitability with ROE at -15.55% and no current revenue, but has made significant progress on its Arkansas lithium project with recent offtake agreements and government support. Analyst consensus remains strongly bullish with 100% buy ratings and a $3.83 price target, representing 168% upside potential from current levels.
The investment case hinges on successful execution of the South West Arkansas project, which could begin production in 2029. Key risks include negative cash flow from operations, high capital requirements, and project timeline delays. The stock offers speculative upside if the company can transition from development to production phase successfully.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →
